Drug companies like Acumen Pharmaceuticals invest millions in products that, if they work, might change the world.
Imagine the impact of a drug that cured, or even slowed the progression of Alzheimer’s. That would change the lives of millions of people, and in some ways, the course of humanity.
But the risk these companies take is that the drugs won’t work after millions have been invested and years spent in development. Sometimes a drug seems promising through trials, making it far along in the process, but ultimately failing.
That can devastate a company, and in the case of Acumen Pharmaceuticals, push it into a Chapter 11 bankruptcy filing.
Acumen Pharmaceuticals drops its Alzheimer’s drug
Acumen shared on Oct. 30 initial topline data from its Phase 2 ALTITUDE-AD clinical trial of sabirnetug (ACU193) in participants with early Alzheimer’s disease. It did not meet its primary endpoint of change from baseline in cognitive and functional decline, the company shared in a press release.
“The trial also failed to achieve statistical significance on key secondary efficacy endpoints, including the Clinical Dementia Rating — Sum of Boxes (CDR-SB), and did not show any meaningful difference between either sabirnetug treatment arm and the placebo arm,” the company added.
Based on the initial topline results, Acumen plans to cease development of sabirnetug, including the open-label extension portion of the ALTITUDE-AD trial, and to evaluate its strategic options. In the interim, the company plans to take steps to implement cash conservation measures and explore strategic options to maximize shareholder value.
Those moves came in a Nov. 1 SEC filing.
Acumen’s board of directors of the Company (the “Board”) approved certain steps to implement cash conservation measures, “including a reduction of the Company’s workforce by 52 full-time employees, or approximately 90% of the company’s current employee base.”
Acument initiated the layoffs on Nov. 2, 2026, with the majority of impacted positions ending in November 2026 and a small number of positions maintained into early 2027.
“While we are disappointed the trial did not meet its primary endpoint, we express our compassion and hope for future therapeutic options for patients with Alzheimer’s disease and their families,” CEO Daniel O’Connell said in the release.
Acumen has laid off 90% of its workforce. Shutterstock
A quick look at Acumen Pharmaceuticals’ financial trouble
Acumen may not survive its latest setback and has shared that its future remains in doubt.
Lead drug fails clinical trial: On Oct. 30, Acumen announced that its experimental Alzheimer’s drug, sabirnetug (ACU193), failed to meet the primary endpoint in its Phase 2 ALTITUDE-AD clinical trial. The study involved 542 patients with early Alzheimer’s disease, according to a press release.
Development discontinued: Acumen said it would stop developing sabirnetug, including the open-label extension of the clinical trial, and evaluate strategic alternatives for its remaining technology, according to an SEC filing.
90% of workforce eliminated: The company’s board approved a reduction of 52 full-time employees, approximately 90% of its workforce, on Nov. 1. Most affected employees were expected to leave in November, with a small number retained into early 2027, according to an 8-K.
$7.75 million restructuring costs: Acumen estimates it will spend approximately $7.75 million on severance and related expenses. Most charges are expected in Q4 2026 and Q1 2027.
Going concern warning: In its third-quarter 2026 filing, Acumen disclosed substantial doubt about its ability to continue as a going concern.
Cash reserves dwindling: As of Sept. 30, 2026, Acumen had $78.6 million in cash, cash equivalents, and marketable securities, compared with an accumulated deficit of $525.3 million, according to its third-quarter filing.
Cash runway: The company said its available cash was not expected to fund operations for at least 12 months from the financial statements’ issuance. Management expected its cash to last into early 2027.
Alzheimer’s patients have other hopes
The seeming end of Acumen does not mean that Alzheimer’s patients should despair. There are many other drugs in the current pipeline.
Compared to a decade ago, there are substantially more drugs (+35%) being tested for Alzheimer’s disease in more clinical trials (+40%) targeting a greater number of aspects of the disease, according to a new analysis of Alzheimer’s disease drug development as reflected in clinical trials registered on clinicaltrials.gov.“The current drug development pipeline provides the basis for optimism regarding the emergence of new therapies for patients with Alzheimer’s. There are a robust number of trials, and agents in trials target a variety of disease processes,” said Jeffrey Cummings, M.D., Joy Chambers-Grundy Professor of Brain Science, Department of Brain Health, University of Nevada, Las Vegas, and lead author of the paper.
He offered hope for people fighting the dreaded diseases.
“Alzheimer’s is no longer an untreatable disease. It is now a disease with treatments that successfully interfere in the disease process,” he said. “Progress is also evident in clinical trial design, integration of biomarkers into trials, and emergence of promising candidate therapies. Biomarkers are increasingly used for trial eligibility as well as being integrated as trial outcomes.”
Related: 57-year-old children’s apparel chain files Chapter 11 bankruptcy